Carroll Financial Associates’s 10x Genomics TXG Stock Holding History

Carroll Financial Associates’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	$3K	Buy	+27	New	+$4.14K	﹤0.01%	1456

Other funds holding TXG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Carroll Financial Associates's TXG Position: Q4 2021 in Review

Carroll Financial Associates opened a new position in 10x Genomics (TXG) in Q4 2021: 27 shares worth $3K. The stake represents ﹤0.01% of the portfolio and ranks #1456 among its holdings.

365 funds tracked by Wall St. Rank hold TXG as of Q4 2021.

Carroll Financial Associates held 27 shares of 10x Genomics worth $3K as of Q4 2021.
10x Genomics was a new Carroll Financial Associates position in Q4 2021.
10x Genomics made up ﹤0.01% of Carroll Financial Associates's portfolio in Q4 2021, its #1456 holding.
365 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2021.

Based on Carroll Financial Associates's 13F filing for Q4 2021, filed 6 Jan 2022.